Cyanoguanidine prodrugs

Details Cyanoguanidine prodrugs Cyanoguanidine prodrugs

2007-08-07

2007-08-07

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S306000

Reexamination Certificate

active

10514500

ABSTRACT:
Pyridyl cyanoguanidine compounds of the general formula I wherein A, X1, X2, X3, Y1, Y2, Y3, R1, R2, R5, R6and n are as indicated in the description are suitable as prodrugs in human and veterinary therapy of proliferative diseases such as cancers.

REFERENCES:
patent: 5919816 (1999-07-01), Hausheer et al.
patent: 6525077 (2003-02-01), Binderup et al.
patent: 2003/0045515 (2003-03-01), Binderup et al.
patent: 2006/0014804 (2006-01-01), Binderup
patent: 0 660 823 (1996-08-01), None
patent: WO-98/54141 (1998-12-01), None
patent: WO-98/54142 (1998-12-01), None
patent: WO-98/54143 (1998-12-01), None
patent: WO-98/54144 (1998-12-01), None
patent: WO-98/54145 (1998-12-01), None
patent: WO-00/61559 (2000-10-01), None
patent: WO-00/61561 (2000-10-01), None
patent: WO-02/42265 (2002-05-01), None
patent: WO-02/094322 (2002-11-01), None
patent: WO-03/97601 (2003-11-01), None
patent: WO-03/097602 (2003-11-01), None
Davidsen et al., “N-(acyloxyalkyl) pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonist”, Journal of Medicinal Chemistry, Dec. 23, 1994, vol. 37, No. 26, pp. 4423-4429.
Bodor et al., “Soft alkylating compounds as potential antitumor agents”, Journal of Medicinal Chemistry, 1980, vol. 23, No. 5, pp. 566-569.
Hjamaa, P. et al. “CHS 828, a Novel Pyridyl Cyanoguanidine with Potent Antitumor Activity in Vitro and in Vivo,” Cancer Research 59, 5751-5757, Nov. 15,1999.
Schou, C. et al. “Novel Cyanoguanidines with Potent Oral Antitumour Activity,” Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 24, pp. 3095-3100, 1997.
Svensson, A. et al. “CHS 828 Inhibits Neuroblastoma Growth in Mice Alone and in Combination with Antiangiogenic Drugs,”Pediatric Research, vol. 51, No. 5, 2002, pp. 607-611.
Olsen, L.S. et al., “Anticancer Agent CHS 828 Suppresses Nuclear Facor-KB Activity in Cancer Cells through Downregulation of IKK Activity”,Int. J. Cancer,vol. 111, pp. 198-205, 2004.

Affiliated with

Also associated with

Rating

Cyanoguanidine prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyanoguanidine prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanoguanidine prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3831463